Lixte Biotechnology Holdings, Inc. (LIXT)
NASDAQ: LIXT · Real-Time Price · USD
3.400
-0.250 (-6.85%)
At close: Jan 12, 2026, 4:00 PM EST
3.600
+0.200 (5.88%)
After-hours: Jan 12, 2026, 6:05 PM EST
LIXT Employees
Lixte Biotechnology Holdings had 2 employees as of December 31, 2024. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change (1Y)
-2
Growth (1Y)
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$2,066,844
Market Cap
29.62M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2 | -2 | -50.00% |
| Dec 31, 2023 | 4 | 0 | - |
| Dec 31, 2022 | 4 | 0 | - |
| Dec 31, 2021 | 4 | 0 | - |
| Dec 31, 2020 | 4 | 3 | 300.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LIXT News
- 20 days ago - LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial - GlobeNewsWire
- 5 weeks ago - LIXTE's Strategy Comes Into Focus: Building an Oncology Platform Around Complementary Modalities - Accesswire
- 5 weeks ago - LIXTE Levels Up From PP2A Innovation to Multi-Modal Oncology - Accesswire
- 5 weeks ago - LIXTE Steps Into a Key Role in the Rise of Treatment Amplifiers - Accesswire
- 6 weeks ago - LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment - GlobeNewsWire
- 2 months ago - LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3 - GlobeNewsWire
- 3 months ago - LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans - GlobeNewsWire
- 4 months ago - LIXTE's Bold Blueprint to Rewire Cancer's Master Switch and Redefine Its Own Future (NASDAQ: LIXT) - Accesswire